European Partnership for Pandemic Preparedness (Phase 2)

Overview

A continuation of the European Partnership for Pandemic Preparedness, this grant expands existing activities to strengthen EU-wide clinical research networks, coordination mechanisms, and pandemic preparedness infrastructure. It targets the consortium previously funded under HORIZON-HLTH-2024-DISEASE-12-01, with potential for additional partners, to enhance transnational collaboration and response capabilities.

Who Can Apply

The coordinator of the consortium funded under the initial "European Partnership for Pandemic Preparedness" (HORIZON-HLTH-2024-DISEASE-12-01) must submit the proposal. Additional partners may be included, provided the existing consortium framework is maintained. Legal entities from the United States are eligible for EU funding with consortium agreement.

Funding Details

• Maximum grant amount: €63,000,000
• Funding rate: 50% of eligible costs
• Financial support to third parties (FSTP): Up to €3,000,000 per third party for the partnership’s duration, with potential for higher amounts if justified.

What Is Funded

• Expansion of clinical research networks (observational and interventional studies) with capacity for rapid response to public health emergencies.
• Coordination with the Clinical Trial Coordination Mechanism (CT-CM) to align research needs and funding.
• Transnational research across basic, pre-clinical, clinical, public health, and social sciences, adopting a One Health approach.
• Integration of environmental, ecological, and climatic factors into pandemic preparedness research.
• Development of a health research data ecosystem aligned with the European Health Data Space (EHDS) and European Open Science Cloud (EOSC).
• Engagement of SMEs, start-ups, and private/philanthropic actors to strengthen innovation and commercial exploitation.
• Widening participation of underrepresented countries and stakeholders in the European Research Area.

Technology / Maturity Requirements

• TRL range: 4 to 6 (technology validated in lab to prototype demonstrated in relevant environment).

Key Dates

• Open date: 2027-02-09
• Deadline: 2027-04-12T22:00:00Z

Application Process (High-Level)

• Single-stage process: Proposal submission by the existing consortium coordinator, outlining additional activities and partners.
• Evaluation criteria: Excellence (threshold 4), Impact (threshold 4), Implementation (threshold 4), with a cumulative threshold of 12.
• Submission portal: Funding & Tenders Portal.

Post-Award Obligations

• Compliance with ethical, regulatory, and legal frameworks.
• Timely translation of research outcomes into clinical and public health policy.
• Reporting and dissemination aligned with EU standards, including integration with EHDS and EOSC.
• Potential restrictions on ownership transfer or exclusive licensing of results for up to 4 years post-award.

Geographic Scope & Language

• Eligible countries: EU Member States, Associated Countries (Norway, Iceland, United Kingdom, Switzerland), and the United States (with consortium agreement).
• Application language: English.

Notes

• The grant is an amendment to an existing agreement, requiring justification for additional activities and partners.
• Synergies with EU4Health, Digital Europe Programme, and other EU initiatives are encouraged.
• Financial support to third parties is a core activity, with no €60,000 threshold due to the partnership’s objectives.